Search Result

Results for "

Alpha3 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) AAK1 (1) Akt (1) Amyloid-β (1) Apoptosis (9) Autophagy (7) Biochemical Assay Reagents (1) CDK (7) CFTR (1) Cholinesterase (ChE) (3) Cuproptosis (2) DNA-PK (2) DNA/RNA Synthesis (1) Drug Isomer (1) DYRK (1) Environmental Pollutants (1) ERK (2) GABA Receptor (4) GDNF Receptor (1) Glycine Receptor (GlyR) (1) Glycosidase (1) GSK-3 (24) Integrin (2) Isotope-Labeled Compounds (4) JNK (2) Microtubule/Tubulin (6) MMP (1) Molecular Glues (1) Na+/K+ ATPase (2) nAChR (12) NF-κB (2) NOD-like Receptor (NLR) (5) p38 MAPK (2) Parasite (2) Pim (1) PKA (1) PKC (2) Reactive Oxygen Species (ROS) (2) Reference Standards (6) STAT (1) Tau Protein (3) β-catenin (1)
By Research Areas:	Cancer (27) Infection (7) Inflammation/Immunology (7) Metabolic Disease (7) Neurological Disease (29)

By Targets:

5-HT Receptor (1)

AAK1 (1)

Akt (1)

Amyloid-β (1)

Apoptosis (9)

Autophagy (7)

Biochemical Assay Reagents (1)

CDK (7)

CFTR (1)

Cholinesterase (ChE) (3)

Cuproptosis (2)

DNA-PK (2)

DNA/RNA Synthesis (1)

Drug Isomer (1)

DYRK (1)

Environmental Pollutants (1)

ERK (2)

GABA Receptor (4)

GDNF Receptor (1)

Glycine Receptor (GlyR) (1)

Glycosidase (1)

GSK-3 (24)

Integrin (2)

Isotope-Labeled Compounds (4)

JNK (2)

Microtubule/Tubulin (6)

MMP (1)

Molecular Glues (1)

Na+/K+ ATPase (2)

nAChR (12)

NF-κB (2)

NOD-like Receptor (NLR) (5)

p38 MAPK (2)

Parasite (2)

Pim (1)

PKA (1)

PKC (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (6)

STAT (1)

Tau Protein (3)

β-catenin (1)

By Research Areas:

Cancer (27)

Infection (7)

Inflammation/Immunology (7)

Metabolic Disease (7)

Neurological Disease (29)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12040

Elesclomol Maximum Cited Publications 115 Publications Verification STA-4783	Reactive Oxygen Species (ROS) Apoptosis Cuproptosis	Cancer
Elesclomol (STA-4783) is a potent copper ionophore and promotes copper-dependent cell death (cuproptosis). Elesclomol specifically binds ferredoxin 1 (FDX1) α2/α3 helices and β5 strand. Elesclomol inhibits FDX1-mediated Fe-S cluster biosynthesis. Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer. Elesclomol can be used for Menkes and associated disorders of hereditary copper deficiency research .

HY-16569

Colchicine Maximum Cited Publications 62 Publications Verification	Environmental Pollutants Apoptosis Autophagy Microtubule/Tubulin NOD-like Receptor (NLR)	Cancer
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .

HY-16294

LY2090314 15+ Cited Publications	GSK-3	Cancer
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

HY-N0877

Bufalin 5+ Cited Publications	Na+/K+ ATPase	Cancer
Bufalin is an active component isolated from Chan Su, acts as a potent Na ⁺/K ⁺-ATPase inhibitor, binds to the subunit α1, α2 and α3, with K_d of 42.5, 45 and 40 nM, respectively . Anti-cancer activity .

HY-12012

SB 216763 40+ Cited Publications	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

HY-14571

E7820 5 Publications Verification ER68203-00	Molecular Glues Integrin	Infection Metabolic Disease Cancer
E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a molecular glue that induces the targeted degradation of splicing factor RBM39 by recruiting the E3 ubiquitin ligase CUL4-RBX1-DDB1-DCAF15 (CRL4 ^DCAF15). E7820 is an angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC₅₀ of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. E7820 can be used for the study of acute myeloid leukemia (AML) .

HY-15761

AZD2858 5+ Cited Publications	GSK-3	Neurological Disease
AZD2858 is a potent, orally active GSK-3 inhibitor, with IC₅₀s of 0.9 and 5 nM for *GSK-3α* and GSK-3β, respectively, used in the research of fracture healing.

HY-P2358

PSMα3	NF-κB p38 MAPK	Infection Inflammation/Immunology
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK. PSMα3 forms membrane pores and binds to residues of human insulin B chain to inhibit insulin aggregation. PSMα3 forms α-type amyloid-like fibrils to exert cytotoxic effects, and acts as a functional amyloid virulence determinant of Staphylococcus aureus. PSMα3 is applicable to research related to spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and Staphylococcus aureus infection .

HY-13076

CHIR-98014 5+ Cited Publications	GSK-3	Metabolic Disease
CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC₅₀s of 0.65 and 0.58 nM for *GSK-3α* and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.

HY-A0009

Galanthamine hydrobromide 10+ Cited Publications Galantamine hydrobromide	Cholinesterase (ChE) nAChR	Neurological Disease
Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-B0379A

Adiphenine hydrochloride 3 Publications Verification	nAChR	Neurological Disease
Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC₅₀s of 1.9, 1.8, 3.7, and 6.3 μM for α1, *α3β4, α4β2, and α4β4*, respectively. Adiphenine hydrochloride has anticonvulsant effects .

HY-107531

A 1070722	GSK-3	Neurological Disease Cancer
A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .

HY-N7110

6-Hydroxyflavone 2 Publications Verification	Akt ERK JNK GABA Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
6-Hydroxyflavone is an orally effective flavonoid compound. 6-Hydroxyflavone can inhibit LPS (HY-D1056) -induced NO production and has anti-inflammatory effects. 6-Hydroxyflavone promotes osteoblast differentiation by activating AKT, ERK 1/2 and JNK signaling pathways. 6-Hydroxyflavone has an inhibitory effect on bovine hemoglobin (BHb) glycosylation. 6-Hydroxyflavone has a kidney protective effect. In addition, 6-Hydroxyflavone enhances GABA-induced current through the Benzodiazepine sites of γ-aminobutyric acid (GABA_A) receptors. 6-Hydroxyflavone shows a clear preference for α2 - and α3 - subtypes, which play an anti-anxiety role .

HY-15438

SB 415286 5+ Cited Publications	GSK-3 Apoptosis	Metabolic Disease
SB 415286 is a potent and selective cell permeable inhibitor of *GSK-3α, with an IC₅₀* of 77.5 nM, and a K_i of 30.75 nM; SB 415286 is equally effective at inhibiting human *GSK-3α* and GSK-3β.

HY-P5960

PTBP1-RNA-binding inhibitor P6 TFA PTBP1 α3-helix derived peptide P6 TFA	DNA/RNA Synthesis	Others
PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .

HY-119940

MC180295 1 Publications Verification (rel)-MC180295	CDK	Cancer
MC180295 ((rel)-MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC₅₀ of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect .

HY-154851

GSK-3 inhibitor 3	GSK-3 CDK Tau Protein	Neurological Disease
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3, with IC₅₀s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC₅₀ of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research .

HY-147428

Zolunicant MM-110; (±)-18-Methoxycoronaridine	nAChR Parasite	Infection Neurological Disease
Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC₅₀ of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse . Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis .

HY-148561

CDK8-IN-12	CDK GSK-3 PKC	Cancer
CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a K_i of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with K_is of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent .

HY-122026

PF-04802367 PF-367	GSK-3	Neurological Disease
PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC₅₀ of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC₅₀ values of 10.0 and 9.0 nM in mobility shift assays, respectively .

HY-177590

14-3-3-IN-2	MMP	Others
14-3-3-IN-2 is a 14-3-3 protein inhibitor with an IC₅₀ of 15 nM. 14-3-3-IN-2 can disrupt the interaction of 14-3-3α with aminopeptidase N and down-regulate 14-3-3α increased MMP-1 mRNA levels .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, CDK2, and CDK5, with IC₅₀ values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-149054

GSK-3β inhibitor 13	GSK-3 Tau Protein AAK1 Pim PKC	Neurological Disease
GSK-3β inhibitor 13 (compound 47) is an orally active and potent *GSK-3β* inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits GSK-3β and *GSK-3α* with IC₅₀s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC₅₀=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease .

HY-111379

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively .

HY-111055

BIP-135	GSK-3	Neurological Disease
BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC₅₀s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect .

HY-16569B

Colchicine,suitable for plant cell culture	Biochemical Assay Reagents Microtubule/Tubulin	Inflammation/Immunology Cancer
Colchicine,suitable for plant cell culture, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine,suitable for plant cell culture can be used for plant cell culture .

HY-16569R

Colchicine (Standard)	Reference Standards Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis	Cancer
Colchicine (Standard) is the analytical standard of Colchicine. This product is intended for research and analytical applications. Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .

HY-P10934

LXY3 LXY2	Integrin	Cancer
LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer .

HY-149483

CVN417	nAChR	Neurological Disease
CVN417 is an orally active α6 subunit-containing nAChR antagonist, modulating phasic dopaminergic neurotransmission in an impulse-dependent manner. CVN417 inhibits Ca(2+) effluents mediated by nAChR subunits with IC₅₀s of 0.086 μM (α6), 2.56 μM (α3) and 0.657 μM (α4), respectively. CVN417 attenuates resting tremor in Rodent models, displays the potential to improve movement dysfunction, in conditions such as Parkinson's disease .

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Inflammation/Immunology Cancer
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 μM) and GSK-3β (IC₅₀=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research .

HY-114791

Lobelanidine	nAChR	Neurological Disease
Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC₅₀ of 2.8 and 8.2 μM .

HY-16569S

Colchicine-d6	Isotope-Labeled Compounds Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis	Cancer
Colchicine-d₆ is the deuterium labeled Colchicine. Colchicine is a tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM . Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs) .

HY-16569S1

Colchicine-d3	Isotope-Labeled Compounds Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis	Cancer
Colchicine-d₃ is the deuterium labeled Colchicine. Colchicine is a tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM . Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs) .

HY-161751

MJ34	GSK-3	Cancer
MJ34 is a potent inhibitor of GSK-3β and *GSK-3α, with the IC₅₀*s of 15.4 nM and 31.5 nM, respectively. MJ34 plays an important role in cancer research

HY-170491

GSK-3β inhibitor 23	GSK-3	Infection Neurological Disease
GSK-3β inhibitor 23 (Compound 11726169) is the inhibitor for glycogen synthase kinase-3, that inhibits GSK-3β and *GSK-3α* with IC₅₀ of 12.1 nM and 18.8 nM. GSK-3β inhibitor 23 exhibits antiviral activity against HIV 1. GSK-3β inhibitor 23 exhibits good metabolic stablility in mouse/human liver microsomes and plasma, but poor Caco-2 permeability (which predicts low oral bioavailability) .

HY-12040S

Elesclomol-d2 STA-4783-d₂	Isotope-Labeled Compounds Reactive Oxygen Species (ROS) Apoptosis Cuproptosis	Cancer
Elesclomol-d₂ (STA-4783-d₂) is a deuterium labeled Elesclomol (HY-12040). Elesclomol (STA-4783) is a potent copper ionophore and promotes copper-dependent cell death (cuproptosis). Elesclomol specifically binds ferredoxin 1 (FDX1) α2/α3 helices and β5 strand. Elesclomol inhibits FDX1-mediated Fe-S cluster biosynthesis. Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer. Elesclomol can be used for Menkes and associated disorders of hereditary copper deficiency research .

HY-161595

CDK5-IN-4	CDK GSK-3	Cancer
CDK5-IN-4 (compound 4) is a potent multikinase type-II inhibitor targeting CDK5, with an IC₅₀ of 9.8 μM. CDK5-IN-4 also inhibits GSK-3α, GSK-3β, CDK9, and CDK2, with IC₅₀ values of 0.98, 4.00, 1.76, and 6.24 μM, respectively. CDK5-IN-4 can be used for glioblastoma research .

HY-A0009R

Galanthamine hydrobromide (Standard) Galantamine hydrobromide (Standard)	nAChR Cholinesterase (ChE) Reference Standards	Neurological Disease
Galanthamine (hydrobromide) (Standard) is the analytical standard of Galanthamine (hydrobromide). This product is intended for research and analytical applications. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-163840

GFRα2/3-IN-1	GDNF Receptor	Neurological Disease
GFRα2/3-IN-1 (Compound 16) is a selective GFRα2/3 inhibitor with IC₅₀ values of 0.1 and 0.2 μM for GFRα2 and GFRα3, respectively. GFRα2 is a glial cell line-derived neurotrophic factor (GDNF) receptor related to GFRα1, GFRα2/3-IN-1 can be used for pain and itch research .

HY-171807

TC-2559 free base	nAChR STAT	Neurological Disease Inflammation/Immunology
TC-2559 free base is a α4β2 nicotinic acetylcholine receptor (nAChR) agonists with an EC₅₀ of 0.18 μM. TC-2559 free base shows much weaker potencies on the group of b4-containing nAChR subtypes, α2β4, α4β4 and α3β4 receptors, with EC₅₀s in the range of 10-30 µM. TC-2559 free base can increase the discharge of dopamine cells in the ventral tegmental area (VTA) of rats in vitro, enhancing the excitability and aggressive behavior of VTA dopamine neurons. TC-2559 free base inhibits STAT3 to exert anti-inflammatory properties and relieves mice mechanical allodynia and improve rats cognitive deficits. TC-2559 free base can be used for the study of nerve pain .

HY-P2358A

PSMα3 TFA	NF-κB p38 MAPK	Infection Inflammation/Immunology
PSMα3 TFA is an inhibitor of NF-κB p65 and p38 MAPK. PSMα3 TFA forms membrane pores and binds to residues of human insulin B chain to inhibit insulin aggregation. PSMα3 TFA forms α-type amyloid-like fibrils to exert cytotoxic effects, and acts as a functional amyloid virulence determinant of Staphylococcus aureus. PSMα3 TFA is applicable to research related to spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and Staphylococcus aureus infection .

HY-N11477

(2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid	Glycosidase	Metabolic Disease
(2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid is a saponin that can be isolated from Rubus ellipticus var. obcordatus. (2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid inhibits *α-Glucosidase* with an IC₅₀ of 1.68 mM .

HY-15438R

SB 415286 (Standard)	GSK-3 Apoptosis	Metabolic Disease
SB 415286 (Standard) is the analytical standard of SB 415286. This product is intended for research and analytical applications. SB 415286 is a potent and selective cell permeable inhibitor of GSK-3α, with an IC50 of 77.5 nM, and a Ki of 30.75 nM; SB 415286 is equally effective at inhibiting human GSK-3α and GSK-3β.

HY-162722

GSK-3 inhibitor 6	GSK-3	Others
GSK-3 inhibitor 6 (2) is a CNS penetrated GSK-3 inhibitor, with IC₅₀ values of 29 nM and 24 nM for GSK-3α and GSK-3β, respectively .

HY-100706

AMA-37	DNA-PK	Cancer
AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC₅₀ values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively .

HY-12012R

SB 216763 (Standard)	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 (Standard) is the analytical standard of SB 216763. This product is intended for research and analytical applications. SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC50s of 34.3 nM for both GSK-3α and GSK-3β.

HY-N10132

Microgrewiapine A	nAChR	Infection Neurological Disease
Microgrewiapine A is an antagonist of nAChR. Microgrewiapine A inhibits hα4β2 and hα3β4 activity with 60% and 70% inhibition, respectively. Microgrewiapine A has selective cytotoxic against HT-29 human colon cancer cells with an IC₅₀ of 6.8 μM .

HY-N0877R

Bufalin (Standard)	Reference Standards Na+/K+ ATPase	Cancer
Bufalin (Standard) is the analytical standard of Bufalin. This product is intended for research and analytical applications. Bufalin is an active component isolated from Chan Su, acts as a potent Na+/K+-ATPase inhibitor, binds to the subunit α1, α2 and α3, with Kd of 42.5, 45 and 40 nM, respectively . Anti-cancer activity .

HY-121141

Adiphenine	nAChR	Neurological Disease
Adiphenine is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC₅₀s of 1.9, 1.8, 3.7, and 6.3 μM for α1, *α3β4, α4β2, and α4β4*, respectively. Adiphenine has anticonvulsant effects .

HY-117106

PNU-107484A	GABA Receptor	Others
PNU-107484A is a GABA_A receptor ligand that exhibits target activity mechanisms dependent on α isoforms. In the α1β2γ2 subtype, PNU-107484A acts as a positive allosteric modulator, enhancing GABA-induced Cl ^- currents, while it inhibits the currents in the α3β2γ2 and α6β2γ2 subtypes. The half-maximal concentrations for the α1β2γ2, α3β2γ2, and α6β2γ2 subtypes are 3.1, 4.2, and 3.5 μM, respectively. PNU-107484A can be used as a probe to investigate the physiological roles of different α isoform subtypes .

Cat. No.	Product Name	Type

HY-16294G

LY2090314	Fluorescent Dyes
LY2090314 (GMP) is LY2090314 (HY-16294) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

Cat. No.	Product Name	Type

HY-16569B

Colchicine,suitable for plant cell culture

Biochemical Assay Reagents

Colchicine,suitable for plant cell culture, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine,suitable for plant cell culture can be used for plant cell culture .

HY-16294G

LY2090314	Biochemical Assay Reagents
LY2090314 (GMP) is LY2090314 (HY-16294) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

Cat. No.	Product Name	Target	Research Area

HY-P2358

PSMα3	NF-κB p38 MAPK	Infection Inflammation/Immunology
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK. PSMα3 forms membrane pores and binds to residues of human insulin B chain to inhibit insulin aggregation. PSMα3 forms α-type amyloid-like fibrils to exert cytotoxic effects, and acts as a functional amyloid virulence determinant of Staphylococcus aureus. PSMα3 is applicable to research related to spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and Staphylococcus aureus infection .

HY-P5960

PTBP1-RNA-binding inhibitor P6 TFA PTBP1 α3-helix derived peptide P6 TFA	DNA/RNA Synthesis	Others
PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .

HY-P10934

LXY3 LXY2	Integrin	Cancer
LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer .

HY-P5959

PTBP1 α3-helix derived peptide P1 TFA	Peptides	Others
PTBP1α3-helix derived peptide P1 is a polypeptide that inhibits RNA binding .

HY-P2358A

PSMα3 TFA	NF-κB p38 MAPK	Infection Inflammation/Immunology
PSMα3 TFA is an inhibitor of NF-κB p65 and p38 MAPK. PSMα3 TFA forms membrane pores and binds to residues of human insulin B chain to inhibit insulin aggregation. PSMα3 TFA forms α-type amyloid-like fibrils to exert cytotoxic effects, and acts as a functional amyloid virulence determinant of Staphylococcus aureus. PSMα3 TFA is applicable to research related to spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and Staphylococcus aureus infection .

Cat. No.	Product Name	Chemical Structure

HY-16569S

Colchicine-d6
Colchicine-d₆ is the deuterium labeled Colchicine. Colchicine is a tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM . Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs) .

HY-16569S1

Colchicine-d3
Colchicine-d₃ is the deuterium labeled Colchicine. Colchicine is a tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM . Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs) .

HY-12040S

Elesclomol-d2

Elesclomol-d₂ (STA-4783-d₂) is a deuterium labeled Elesclomol (HY-12040). Elesclomol (STA-4783) is a potent copper ionophore and promotes copper-dependent cell death (cuproptosis). Elesclomol specifically binds ferredoxin 1 (FDX1) α2/α3 helices and β5 strand. Elesclomol inhibits FDX1-mediated Fe-S cluster biosynthesis. Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer. Elesclomol can be used for Menkes and associated disorders of hereditary copper deficiency research .

HY-A0009S

Galanthamine-d3 hydrobromide

Galanthamine-d₃ (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16294G

LY2090314	GSK-3	Cancer
LY2090314 (GMP) is LY2090314 (HY-16294) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Alpha3 Inhibitors

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products